BioVie Inc. (Class A) (BIVI) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, BioVie Inc. (Class A) (NASDAQ: BIVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.38 (-5.48% 1D, market cap $12.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BIVI ranks #881 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIVI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and ASBP (Aspire-Lakewood Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M). Among the 5-stock peer group, BIVI leads on earnings multiple (N/A) while BIVI leads on capital efficiency (-35.0% ROIC).
Per BIVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001580149), BioVie Inc. (Class A) generated $0 in revenue, -$17.5M in net income, and -$19.0M in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 51.1 (NEUTRAL RANGE)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While BIVI currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.64) and Max Pain ($1.45) forces dealer call-delta covering toward $3.98.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BioVie Inc. (Class A) (BIVI) dropped -5.48% to $1.38, trading at 19% of its 52-week range ($0.82 – $3.79). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Stewards Investment Capital, FreeCast (NASDAQ:CAST) and BioVie (NASDAQ:BIVI) Headline a Four-Region Broadcast Across the U., Latin America, MENA and Southeast AsiaNEW YORK CITY, NY / ACCESS Newswire / October 31, 2026 /
CARSON CITY, Nev., Oct. 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases,
2:30pm: Market movers SpaceX Corp (NASDAQ:SPCX) has committed to an approximately $40 billion finance lease for Nvidia's next-generation Vera Rubin chips and related equipment through an entity managed by Apollo Global M
Stewards Investment Capital, BioVie, FreeCast and American Fusion Headline a Four-Region Broadcast Across the U., Latin America, MENA and Southeast AsiaNEW YORK CITY, NY / ACCESS Newswire / October 24, 2026 / Where capit
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Ph
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at
Parkinson’s patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo. CARSON CITY, Nev., Oct. 20, 2026 (GLOBE NE
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) CEO Cuong Do joined Proactive's Stephen Gunnion after the company presented findings from its Long COVID and Parkinson’s disease trials at the American Neurological Association’s An
Phase 2 data from the ADDRESS-LC trial of Bezisterim demonstrated statistically significant improvements versus placebo across fatigue, post-exertional malaise, and objective cognitive measures in Long COVID patients wit
4:20pm: Tech shares recover Wall Street ended mixed on Monday as a rebound in technology stocks lifted the S&P 500 and Nasdaq, while the Dow Jones slipped slightly as investors turned their attention to a busy week of co
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BIVI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BIVI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BioVie Inc. (Class A) (BIVI) ranks #881 by composite RQD confidence (33/100, grade E) and #879 by equity capitalization ($12.0M). Within this direct 5-issuer industry benchmark cohort, BIVI leads on earnings valuation at N/A trailing P/E, while BIVI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CALC currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with BIVI at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BIVI
ACTIVE
BioVie Inc. (Class A) | E | 33/100 | — | — | -35.0% | -5.48% | $12.0M | Benchmark Subject |
| CALC CalciMedica Inc. | D | 47/100 | — | — | -35.0% | +5.42% | $11.9M | /calc-vs-bivi → |
| ASBP Aspire-Lakewood Holdings Inc. | E | 33/100 | — | -1.9% | -35.0% | -4.50% | $11.9M | /asbp-vs-bivi → |
| BOLT Bolt Biotherapeutics Inc. | E | 28/100 | — | — | -35.0% | -3.34% | $12.3M | /bolt-vs-bivi → |
| HIND Vyome Holdings Inc. | D- | 35/100 | — | 68.4% | -35.0% | +1.74% | $12.3M | /hind-vs-bivi → |
In its most recent audited fiscal period (FY2025, filed 2025-06-30), BioVie Inc. (Class A) (BIVI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$17.5M, operating cash flow of -$19.0M, and free cash flow of -$19.0M (+31.9% YoY). On the balance sheet, BIVI closed FY2025 with $22.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $0 | -$17.5M | -$19.0M | -$19.0M | $22.5M | — |
| FY2024 (FY) | 2024-06-30 | $0 | -$32.1M | -$27.9M | -$27.9M | $25.7M | — |
| FY2023 (FY) | 2023-06-30 | $0 | -$50.3M | -$40.3M | -$40.3M | — | — |
As of 2026-11-01, BioVie Inc. (Class A) (NASDAQ: BIVI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.38 (-5.48% 1D, market cap $12.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BIVI ranks #881 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIVI carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CALC (CalciMedica Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and ASBP (Aspire-Lakewood Holdings Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M). Among the 5-stock peer group, BIVI leads on earnings multiple (N/A) while BIVI leads on capital efficiency (-35.0% ROIC).
Per BIVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001580149), BioVie Inc. (Class A) generated $0 in revenue, -$17.5M in net income, and -$19.0M in free cash flow against $22.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BIVI last traded at $1.38 (-5.48% on volume of 41,879 shares), positioning the stock -15.85% below its 50-day simple moving average ($1.64) and -9.21% below its 200-day simple moving average ($1.52). Across its 52-week range of $0.82 to $3.79, BIVI sits at the 18.9% percentile with a 14-day RSI of 51.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.21 to $1.55).
Why BIVI Stock dropped -5.48% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.